Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Celsion's DIGNITY clinical trial aired on Good Morning America

Celsion Corporation announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.

16 Sep 2009

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they have formed a partnership to provide education to physicians and liver patients about the treatment options for hepatocellular carcinoma (commonly referred to as primary liver cancer) and Celsion’s on-going ThermoDox Phase III global HEAT clinical study.

14 Sep 2009

Accupac to manufacture Access Pharmaceuticals' MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

11 Sep 2009

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.

11 Sep 2009

Third-quarter fiscal 2009 results announced by MDS

MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today reported financial results for the three-month period ended July 31, 2009. MDS reported total revenue of $199 million, a net loss of $62 million and a loss per share of $0.51 for the third quarter of 2009, compared with $252 million in total revenue, a net loss of $10 million and a loss per share of $0.08 for the same period last year.

10 Sep 2009

Nasdaq Stock Market issues delisting notice to Metabasis Therapeutics

Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the “Staff”) notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff’s delisting determination, trading of the Company’s common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.

10 Sep 2009

Physicians to educate Congress on the importance of reducing viral hepatitis

The National Viral Hepatitis Roundtable (NVHR) is hosting a briefing, "The Experts' Perspective: Gaps and Strategies in the Hepatitis Crisis." "Leading hepatitis physicians, one of whom is a Congressman, will be on the hill today to educate Congress on the importance of developing a strategy to reduce the significant morbidity and mortality from end-stage liver disease and liver cancer caused by chronic hepatitis B and chronic hepatitis C in the United States," said Martha Saly, Director of NVHR.

9 Sep 2009

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

9 Sep 2009

Rise in primary liver cancer cases attributed to increased alcohol consumption

Cases of primary liver cancer have tripled in the last 30 years according to statistics published today by Cancer Research UK.

7 Sep 2009

Delcath Systems to present abstract at ILCA Annual Conference

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that Dr. James F. Pingpank, Associate Professor of Surgery for the University of Pittsburgh School of Medicine will present an abstract at the International Liver Cancer Association's (ILCA) Third Annual Conference on Saturday, September 5, 2009 in Milan, Italy.

4 Sep 2009

Banner Good Samaritan treats cancers and neurological disorders with the Novalis Tx radiosurgery platform

John J. Kresl, M.D., Ph.D., and colleagues at Banner Good Samaritan Medical Center are now treating a wide variety of cancers and neurological disorders with highly-accurate, non-invasive, image-guided radiosurgery using the Novalis Tx(TM) radiosurgery platform from Varian Medical Systems (NYSE: VAR) and BrainLAB.

4 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.

3 Sep 2009

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

To address this public health challenge, government, medical and community experts will meet September 10-11 in Washington, D.C. to plan an improved national response to viral hepatitis. The conference "The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C" will feature keynote addresses, panel discussions and scientific poster sessions focused on enhancing the prevention and detection of viral hepatitis and improving care for people who are already living with the disease.

2 Sep 2009

Doxorubicin granted orphan drug designation by the FDA

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.

31 Aug 2009

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Resonant Medical, an innovator in soft tissue planning, image-guidance and adaptive radiotherapy products, today announced that the Company will be exhibiting the next generation of its multi-anatomy Clarity System at the 10th Biennial Meeting of The European Society of Therapeutic Radiology and Oncologists (ESTRO), being held in Maastricht, Netherlands.

27 Aug 2009

Studies suggest that serrated polyps can be precursors of colon cancers

Serrated colorectal polyps include the subgroups hyperplastic polyps, sessile serrated polyps (also called sessile serrated adenomas), and serrated adenomas. Recent studies have found that serrated polyps share molecular features with a subgroup of colon cancers, leading to the hypothesis that serrated polyps can be precursors of cancer through a hyperplastic polyp to serrated adenoma to cancer sequence.

26 Aug 2009

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Ho Jeong and his colleague from Korea presented a case of duodenal obstruction after successful selective transcatheter arterial embolization (TAE) for a duodenal diverticular hemorrhage. Their study will be published on August 14, 2009 in the World Journal of Gastroenterology.

26 Aug 2009

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.

26 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Liver Cancer News and Research

Further Reading

Celsion's DIGNITY clinical trial aired on Good Morning America

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Accupac to manufacture Access Pharmaceuticals' MuGard

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

Third-quarter fiscal 2009 results announced by MDS

Nasdaq Stock Market issues delisting notice to Metabasis Therapeutics

Physicians to educate Congress on the importance of reducing viral hepatitis

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Rise in primary liver cancer cases attributed to increased alcohol consumption

Delcath Systems to present abstract at ILCA Annual Conference

Banner Good Samaritan treats cancers and neurological disorders with the Novalis Tx radiosurgery platform

Medtronic's COPE-HCV clinical study commences

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

Doxorubicin granted orphan drug designation by the FDA

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Studies suggest that serrated polyps can be precursors of colon cancers

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News